IGM Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2017
Net Income	-246.42	-221.1	-165.16	-81.36	-43.13	Upgrade
Depreciation & Amortization	13.69	10.6	7.72	3.58	2.33	Upgrade
Share-Based Compensation	46.55	44.71	25.87	8.45	1.01	Upgrade
Other Operating Activities	-6.05	159.94	6.59	1.44	-5.33	Upgrade
Operating Cash Flow	-192.23	-5.85	-124.98	-67.88	-45.12	Upgrade
Capital Expenditures	-12.38	-10.21	-13.24	-17.5	-2.34	Upgrade
Change in Investments	80.74	-215.44	28.71	75.79	-200.9	Upgrade
Investing Cash Flow	68.36	-225.64	15.46	58.29	-203.24	Upgrade
Share Issuance / Repurchase	115.07	219.38	4.03	216.51	185.58	Upgrade
Debt Issued / Paid	0	0	0	0	15	Upgrade
Other Financing Activities	-	-	-1.56	-1.73	81.68	Upgrade
Financing Cash Flow	115.07	219.38	2.48	214.78	282.26	Upgrade
Net Cash Flow	-8.81	-12.12	-107.05	205.19	33.9	Upgrade
Free Cash Flow	-204.61	-16.06	-138.23	-85.38	-47.45	Upgrade
Free Cash Flow Margin	-9606.20%	-1502.25%	-	-	-	Upgrade
Free Cash Flow Per Share	-3.91	-0.39	-4.13	-2.78	-5.28	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).